NASDAQ:ADVM - Adverum Biotechnologies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.65 +0.03 (+0.45 %)
(As of 04/25/2019 04:00 PM ET)
Previous Close$6.62
Today's Range$6.4897 - $6.75
52-Week Range$2.62 - $7.72
Volume411,772 shs
Average Volume396,763 shs
Market Capitalization$420.29 million
P/E RatioN/A
Dividend YieldN/A
Beta3.18
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-272-6269

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.61 million
Book Value$3.20 per share

Profitability

Net Income$-72,630,000.00
Net Margins-4,505.40%

Miscellaneous

Employees82
Market Cap$420.29 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) released its quarterly earnings data on Wednesday, March, 6th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The biotechnology company earned $0.07 million during the quarter, compared to analysts' expectations of $0.39 million. Adverum Biotechnologies had a negative net margin of 4,505.40% and a negative return on equity of 30.18%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

5 brokers have issued 12-month price objectives for Adverum Biotechnologies' shares. Their predictions range from $4.00 to $11.00. On average, they expect Adverum Biotechnologies' stock price to reach $6.8750 in the next year. This suggests a possible upside of 3.4% from the stock's current price. View Analyst Price Targets for Adverum Biotechnologies.

What is the consensus analysts' recommendation for Adverum Biotechnologies?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adverum Biotechnologies.

What are Wall Street analysts saying about Adverum Biotechnologies stock?

Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
  • 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (3/13/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are downgrading and reducing our 12-month PT to $4 from $12. The new PT is solely based on the ADVM-022 wAMD program, soon to enter P1 testing in 2018. Our changed perspective results from the PR Friday that the company discontinued development of lead asset ADVM-043 for treatment of A1AT deficiency and hit pause on the preclinical HAE program, deciding not to file an IND in 4Q18. Although further clarity on rare disease programs is expected in 1H19, we now see only the wAMD program as a potential driver of value over the next ~12-18 months." (11/4/2018)
  • 3. Chardan Capital analysts commented, "We had previously expressed concerns on ADVM-043. In our 9 August 2018 research, we stated [t]hus even if safety signals are reassuring, there may be some question on efficacy in final data." Based on the failure of DTX101, and uncertainty on the liver tropism of AAVrh10, we saw issues with the design of ADMV-043. Further, a serious of previous failures of AAV-based GT for A1AT from other organizations including AGTC (Neutral) suggest this is a difficult indication to treat with GT. We look for better datasets in the remaining Adverum pipeline. The OPTIC phase I trial of ADVM-022, an AAV7m8-based, intravitreal anti- VEGF GT for wet AMD, is due to begin dosing in 4Q18. 2018 research detailed our concerns on this asset." (11/2/2018)

Has Adverum Biotechnologies been receiving favorable news coverage?

Media stories about ADVM stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adverum Biotechnologies earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Are investors shorting Adverum Biotechnologies?

Adverum Biotechnologies saw a decrease in short interest in April. As of April 15th, there was short interest totalling 2,293,893 shares, a decrease of 29.1% from the March 29th total of 3,237,258 shares. Based on an average trading volume of 382,331 shares, the days-to-cover ratio is currently 6.0 days. Currently, 4.9% of the shares of the stock are sold short. View Adverum Biotechnologies' Current Options Chain.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Immunomedics (IMMU), Nextera Energy Partners (NEP), Chipotle Mexican Grill (CMG), Buckeye Partners (BPL) and Genocea Biosciences (GNCA).

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)
  • Dr. Amber Salzman, Consultant (Age 57)
  • Ms. Leone D. Patterson, CEO, CFO & Director (Age 56)
  • Dr. Jennifer Cheng, VP, Gen. Counsel & Corp. Sec. (Age 46)

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BNP Paribas Arbitrage SA (0.03%). View Institutional Ownership Trends for Adverum Biotechnologies.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was purchased by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $6.65.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $420.29 million and generates $1.61 million in revenue each year. The biotechnology company earns $-72,630,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is http://www.adverum.com.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  242 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  495
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel